Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.43 USD | -0.14% |
|
+1.98% | +32.26% |
05-07 | Transcript : Electromed, Inc., Q3 2024 Earnings Call, May 07, 2024 | |
05-07 | Electromed, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With a 2024 P/E ratio at 28.29 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+32.26% | 125M | C | ||
+4.85% | 216B | B | ||
+9.86% | 190B | B- | ||
+31.11% | 152B | B- | ||
+34.08% | 113B | A- | ||
+1.90% | 64.04B | A- | ||
+19.45% | 54.34B | B+ | ||
+1.63% | 49.21B | B+ | ||
-3.12% | 39.41B | A | ||
+1.93% | 35.99B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ELMD Stock
- Ratings Electromed, Inc.